Albireo Pharma Inc represents core values of integrity, innovation, and collaboration in the pharmaceutical industry. Committed to improving patient lives, Albireo Pharma focuses on developing and commercializing therapeutic products for rare pediatric liver diseases and gastrointestinal disorders. With a patient-centric approach, the company aims to provide effective treatment options and groundbreaking solutions. Albireo Pharma's corporate philosophy is driven by its dedication to scientific excellence, ethical conduct, and maintaining strong partnerships within the healthcare community.

Albireo Pharma Inc is primarily present in the United States, with its headquarters located in Boston, Massachusetts. As a biopharmaceutical company, Albireo focuses on developing and commercializing novel bile acid modulators to treat rare pediatric liver diseases and gastrointestinal disorders. With a strong presence in the US, Albireo Pharma Inc is dedicated to bringing innovative therapies to patients in need, and its expanding pipeline showcases its commitment to advancing medical treatment options in this region.

Albireo Pharma Inc has achieved significant milestones since its establishment. The company has successfully developed and gained regulatory approval for its lead product, Odevixibat, which is indicated for the treatment of progressive familial intrahepatic cholestasis. Albireo has also secured partnerships with key pharmaceutical companies, further enhancing its market presence and global reach. The company's commitment to innovation and clinical advancements has resulted in positive clinical trial results and numerous publications in reputed medical journals. Albireo Pharma Inc continues to demonstrate its dedication to improving patient outcomes through ongoing research and development efforts.

Albireo Pharma Inc. is a pharmaceutical company known for its focus on developing and commercializing innovative therapies for liver diseases. Founded in 2008, Albireo Pharma is headquartered in Boston, Massachusetts. The company is committed to improving the lives of patients suffering from rare and orphan liver diseases through its research and development efforts. Albireo Pharma has a strong portfolio of experimental drugs, including A4250, aimed at addressing cholestatic liver diseases. With a team of experienced professionals, Albireo Pharma strives to advance its pipeline and bring novel treatments to the market to positively impact patients in need.

The main competitors of Albireo Pharma Inc in the market include companies like AstraZeneca, Gilead Sciences, Intercept Pharmaceuticals, and Novartis.

Albireo Pharma Inc is primarily active in the pharmaceutical industry.

The business model of Albireo Pharma Inc. revolves around developing and commercializing novel therapeutics to treat rare pediatric liver diseases and gastrointestinal (GI) disorders. Albireo's innovative approach focuses on targeting bile acid biology, aiming to improve the quality of life for patients. By harnessing their deep understanding of bile acid physiology, the company develops new chemical entities that modulate bile acid homeostasis, providing potential treatments for conditions such as progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome. Albireo Pharma Inc. aims to address unmet medical needs in the field of rare pediatric liver and GI disorders through their research, development, and commercialization efforts.

P/E odnos Albireo Pharma iznosi -10,87.

KUV kompanije Albireo Pharma iznosi 5,72.

AlleAktien kvalitativni skor za Albireo Pharma je 5/10.

očekivana Albireo Pharma promet je 148,29 mil. USD.

Dobit očekivana Albireo Pharma je -78,08 mil. USD.

Albireo Pharma Inc is a biopharmaceutical company specializing in the development and commercialization of therapeutics for the treatment of liver diseases and pediatric metabolic disorders. The company operates in Europe and the US and aims to find innovative solutions to improve the quality of life for patients worldwide. The company has three main business areas: 1. Pediatric metabolic disorders: This area involves the development of therapeutics for rare genetic metabolic disorders, aiming to enable children to survive and have an improved quality of life. The company has already released an approved treatment called Bylvay, which is used for patients with bile acid synthesis defects type 1. Other developments are in the pipeline, including a drug for treating Progressive Familial Intrahepatic Cholestasis Long-term (PFIC L). 2. Liver diseases: Albireo Pharma Inc develops therapeutics to treat liver diseases that occur in both pediatrics and adults. It focuses particularly on conditions where improvement in bile flow is needed, such as pruritus hepatis or primary biliary cholangitis. The drug Odevixibat is being developed to promote bile flow. 3. Research and development: The company utilizes state-of-the-art research methods to develop innovative therapeutics for liver diseases and pediatric metabolic disorders. This includes the development of technologies for more effective drug administration and collaboration with other companies to make the development process more efficient. Albireo's business model is based on the research and development of therapeutics. The company invests a significant portion of its revenue in developing new drugs and building partnerships with other companies to bring them to market more effectively. At the same time, attracting investors and well-known venture capital firms is an important part of the business model. It aims to secure funding for research and development to bring the products to market. In terms of the products offered by Albireo Pharma Inc, there are a variety of drugs that can be utilized in different areas. Bylvay and Odevixibat are among the most significant drugs currently being developed and are already inevitable in the market. However, the research and development of new therapeutics remains an important aspect of the business model, as the company strives to establish a reputation as a frontrunner in the healthcare industry. In summary, Albireo Pharma Inc is an innovative company dedicated to the development of therapeutics to achieve a better quality of life for those with liver diseases and pediatric metabolic disorders. The company invests in research and development of new drugs and collaborates closely with other companies to bring them to market. Its goal is to make significant changes in the healthcare industry and become a reputable company in the field.

Albireo Pharma isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Albireo Pharma trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Albireo Pharma je US01345P1066.

WKN od Albireo Pharma je A2DF99.

Oznaka za praćenje akcija kompanije Albireo Pharma je ALBO.

U poslednjih 12 meseci, Albireo Pharma je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Albireo Pharma će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Albireo Pharma trenutno iznosi .

Albireo Pharma isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Albireo Pharma je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Albireo Pharma se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Albireo Pharma od 25. 8. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 25. 8. 2024..

Isplata poslednje dividende izvršena je 25. 8. 2024..

U godini 2023 kompanija Albireo Pharma je isplatila 0 USD kao dividende.

Dividende od Albireo Pharma se isplaćuju u USD.